In a move that it anticipates will reduce the preclinical failure of drugs due to toxicity, Geron announced late last week that it is collaborating with CXR Biosciences and the Roslin Institute to develop and commercialize human embryonic stem cell-derived hepatocytes for use in drug metabolism and toxicity screens.

The company hopes to be offering ADME/Tox assays based on the hepatocytes by 2005, according to Geron CFO David Greenwood. Neither Geron nor CXR were able to disclose financial details of the agreement, which was announced on May 20.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.